An update from China NT Pharma Group Co., Ltd. ( (HK:1011) ) is now available.
China NT Pharma Group Co., Ltd. has announced an extraordinary general meeting scheduled for February 2025 to consider resolutions related to a new share subscription agreement. The agreement involves the conditional allotment of over 410 million new shares at HK$0.33 per share to Golden Base Investment Limited and Mr. Ieong Iat. The company seeks approval for the transactions outlined in the agreement, including a specific mandate for the share issuance and a Whitewash Waiver to prevent a mandatory general offer to all shareholders. This move could significantly impact the company’s financial structure and shareholder dynamics, pending shareholder approval.
More about China NT Pharma Group Co., Ltd.
YTD Price Performance: -5.56%
Average Trading Volume: 233,109
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: HK$63.31M
For a thorough assessment of 1011 stock, go to TipRanks’ Stock Analysis page.